FGFR2 and cholangiocarcinoma: For example, FDA has approved orally administered Truseltiq (infigratinib) from Brisbane, California-based QED Therapeutics, Inc., under the accelerated approval program for treating patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement.